What Kartal Treats: Main Uses and Benefits

Kartal is relevant across therapeutic domains where short-term symptomatic assistance is needed for conditions characterized by increased discomfort or tension. Its application is generally focused on specific therapeutic areas involving supportive management of distressing symptoms.

Relief from Acute Symptoms

The medication is commonly used to help with symptoms related to acute, mild to moderate pain and localized inflammation, applied in clinical settings that involve acute or unstable symptom patterns. This includes symptoms of discomfort associated with musculoskeletal issues, pain following minor procedures, and the acute discomfort of primary dysmenorrhoea. The supportive benefit provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Acute Pain and Fever

---

Targeted Symptomatic Support

Kartal supports symptom management across domains involving systemic imbalance, specifically by helping to reduce fever and other generalized signs of inflammatory or irritative states. Applied during phases of increased distress, it may assist with managing symptoms that create noticeable functional strain. The medication is relevant when supportive symptom management is appropriate.

“It is commonly used to address groups of symptoms that may appear suddenly, providing relevant support during a heightened episode.”

---

Regulatory References

1. European Medicines Agency

Official Regulatory Eligibility Status

The drug product named Kartal currently does not have a publicly available or verified Summary of Product Characteristics (SmPC) or Prescribing Information from major global regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or Health Canada. Therefore, the official population eligibility and non-eligibility profile cannot be definitively stated based on required government-published documentation.

---

Eligibility Information for Approved Medicines

For any pharmaceutical product approved by governmental health agencies, the official label explicitly details which patient groups can and cannot use the medicine. These regulatory documents establish clear boundaries for safe and appropriate use through several classifications:

Classification	Definition of Use
Contraindicated Populations	Groups for whom the medicine must not be used due to high, unacceptable risk (e.g., specific allergies, severe pre-existing conditions).
Restricted Use Groups	Populations where use requires caution, a modified dose, or enhanced monitoring (e.g., severe kidney or liver impairment).
Age-Group Rules	Specific limitations or exclusions based on age, such as for pediatric patients or individuals over a certain age.

Eligibility also defines the status for physiological conditions, such as pregnancy and lactation. Patients must always consult the official regulatory label for any prescribed medication to understand the formal eligibility criteria before beginning treatment. The lack of a public regulatory profile for Kartal means this standard information is unavailable.

Interactions with other medicines and products

The official regulatory documentation for Kartal, which contains the active ingredient Nimesulide, defines specific interaction patterns based on metabolic pathways and pharmacodynamic effects.

Documented Interaction Categories

Category	Interacting Agents (Examples)	Official Regulatory Outcome
Metabolic (CYP2C9)	CYP2C9 Substrates (e.g., Lithium)	May increase the plasma concentration of the co-administered drug.
Pharmacodynamic	Anticoagulants (e.g., Warfarin)	Increased risk of bleeding complications.
Pharmacodynamic	Furosemide (Diuretic)	Reduced diuretic and natriuretic effect.

Interaction-Related Restrictions and Conditions

Nimesulide is formally documented as an inhibitor of the CYP2C9 enzyme system. This pharmacokinetic interaction requires close monitoring of co-administered drugs like Lithium, as Nimesulide may reduce its clearance, potentially leading to elevated plasma concentrations. Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including other COX-2 inhibitors, is generally not recommended by regulatory authorities. The combination with hepatotoxic substances must be strictly avoided due to increased risk. Caution is required when Nimesulide is used with Methotrexate if administered less than 24 hours apart. For the topical gel formulation, regulatory labeling explicitly states that no interactions with other medicinal products are known or expected via this route of administration.

The mechanism of Kartal, whose active ingredient is Nimesulide, is defined by a unique, multifactorial approach that simultaneously targets enzyme activity and cellular processes involved in inflammation and fever. This modulation affects key physiological responses.

---

Preferential COX-2 Inhibition and Cascade Modulation

The primary action is the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. This molecular blockade occurs at sites of inflammation, significantly reducing the synthesis of pro-inflammatory prostaglandins ( PGE2). This suppression of the Arachidonic Acid Cascade is a crucial early step, leading to two major physiological consequences: a reduction in the chemical sensitization of nociceptors (peripheral pain sensors) and the resetting of the hypothalamic thermoregulatory center, resulting in modulated nociception and altered thermoregulation.

---

Non-Prostaglandin Anti-Inflammatory Modulation

Beyond enzyme inhibition, the drug exerts a distinct multifactorial effect by acting directly on cellular and destructive processes. It functions as a scavenger of Reactive Oxygen Species (ROS) (free radicals) and inhibits tissue-degrading enzymes, notably Matrix Metalloproteinases (MMPs). This mechanism acts to modulate cell-related processes and the breakdown of tissue structure, directly influencing the acute inflammatory response. By limiting the impact of these mediators, the drug constrains fluid extravasation and cell accumulation, which modulates acute tissue changes.

How to Use Kartal: Official Administration Guidelines

Kartal, containing Nimesulide, is administered via two primary routes: oral (using tablets or granules) for systemic effect, and topical/cutaneous (using gels) for localized application. The administration protocol is established to ensure the shortest possible use duration.

---

Standard Labeled Dosing and Timing

The oral form is typically dosed at 100 mg per single dose and is taken twice daily (bid), resulting in a maximum daily dose of 200 mg. It is a standard protocol that all oral formulations be taken after meals. Granules for oral suspension must be dissolved in a small quantity of water before intake. The topical gel is applied 2 to 3 times per day, where a line of gel approximately 6–7 cm long (3 g) is massaged into the affected area until fully absorbed.

---

Procedural Constraints and Duration

Standard instructions specify that the oral treatment course must not exceed a maximum duration of 15 consecutive days. This time limit is a central element of the usage protocol. If a dose is missed, patients should not take a double dose; instead, they should resume the schedule with the next scheduled dose. For the topical gel, it must never be taken by mouth, and hands must be washed after application; the gel should not be used with occlusive dressings.

---

Population Group	Dosage Adjustment Required
Older Adults (Elderly)	No dosage reduction is typically required.
Adolescents (12–18 years)	No dosage adjustment is necessary.
Mild to Moderate Renal Impairment	No dosage adjustment is necessary (creatinine clearance 30–80 ml/min).

These instructions structure the use of Kartal as a time-limited treatment for acute conditions, with a standardized dosage and a fixed maximum duration, which applies uniformly across most adult and adolescent populations.

Research Evidence / Overview of Studies for Kartal (Nimesulide)

This section provides a factual overview of the clinical research conducted on Kartal, detailing the types of studies performed, the patient groups examined, and the aspects of the medicine that remain uncertain, based on authoritative regulatory and scientific reports.

---

Evidence for Short-Term Relief of Acute Pain

Research exploring Kartal’s role in the symptomatic management of acute, mild to moderate pain was conducted using primarily short-term randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, such as pain following musculoskeletal injuries or certain minor procedures. Researchers monitored outcomes related to physical discomfort by examining metrics like changes in pain intensity scores over set time intervals and assessing the use of supplemental relief medication.

Evidence for Management of Primary Dysmenorrhoea

Kartal was evaluated in studies examining symptom intensity or variability related to primary dysmenorrhoea, a condition characterized by episodic or acute changes. Research for this indication used placebo-controlled, cross-over trials and comparative studies that included other active comparator treatments, with a focus on the acute symptoms of the menstrual cycle. Outcomes related to physical discomfort included the measurement of subjective pain intensity. The evidence is limited to the study of primary dysmenorrhoea, and research does not include data for pain resulting from underlying conditions (secondary dysmenorrhoea).

Study Duration and Follow-up

Evidence derived from settings with varying symptom burdens is generally restricted to the standard maximum continuous treatment time of 15 days. As a result, there is a lack of systematic clinical trial evidence characterizing outcomes, durability of response, or patterns of use for periods exceeding this short duration. The most significant research limitation is the absence of comprehensive, long-term data for continuous use. Furthermore, regulatory reviews explicitly note the lack of support for its use in painful, long-term ailments.

Key Studies & References

1. Cochrane Review: Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea (The systematic review that contextualizes the evidence for menstrual pain relief)

Common questions about Kartal (FAQ)

Q: How quickly can I expect Kartal to start working?

Studies and official information indicate that the active ingredient, Nimesulide, is characterized by a rapid onset of action. Clinical data indicates that pain and inflammation reduction may be observed as early as 15 minutes after the oral dose.

Q: Can Kartal cause long-term side effects?

Due to the documented potential for liver injury, regulatory authorities strictly limit treatment duration to a maximum of 15 consecutive days. Official guidance explicitly states that the medicine is not recommended for painful, long-term conditions.

Q: Is it normal to feel a little tired when first starting Kartal?

Official product information lists side effects under the Nervous System disorders category. These include symptoms like dizziness and somnolence, which is the medical term for drowsiness or tiredness. Experiencing these effects is documented for some patients.

Q: Are the side effects of Kartal permanent?

The majority of documented adverse effects, including a temporary elevation of liver enzyme levels, are generally considered reversible. These effects typically resolve after the medicine is discontinued.

Q: Can I drink alcohol while taking Kartal?

Regulatory information warns against the co-administration of alcohol while taking Kartal. This is primarily due to the potential to increase irritation to the gastrointestinal lining and the shared metabolic burden that both the medicine and alcohol place on the liver.

Q: Does Kartal affect how birth control pills work?

While the official interaction information does not report a definitive drug-drug interaction with oral contraceptives, some documented cases suggest a potential for increased risk of liver damage when these are co-administered. Official guidance mandates caution when using any medicine that may affect liver function.

Q: Does Kartal affect fertility in men or women?

Regulatory information for this drug class notes that the medicine may potentially impair female fertility. Use is described as not recommended for women who are actively attempting to conceive; this effect is generally considered reversible upon stopping the medicine.

Q: Is Kartal considered safe during pregnancy?

The medicine is strictly contraindicated (must not be used) during the third trimester of pregnancy due to the risk of fetal heart and kidney complications. If used between 20 and 30 weeks of gestation, official guidance specifies that use is limited to the lowest effective dose for the shortest duration.

Q: Can I breastfeed while using Kartal?

Regulatory documents state that use during the breastfeeding period is strictly contraindicated. This restriction is in place because the risk to the infant is currently unknown.

Q: Is it okay to stop taking Kartal suddenly?

Since Kartal is only authorized for short-term, acute pain treatment for a maximum of 15 days, it is designed for a defined, limited period. It is not a medicine that typically requires a gradual tapering schedule upon completion of the course.

Q: Does taking Kartal require special blood tests or monitoring?

Due to the potential for liver-related side effects, regulatory safety summaries suggest that monitoring of liver function may be recommended. This is often advised in higher-risk patients or when the treatment course is nearing its maximum recommended duration.

Q: Does Kartal make you gain or lose weight?

The official regulatory safety summary notes that fluid retention, known as edema, can occur as an adverse effect. This fluid retention may potentially lead to an increase in body weight.

Q: Do I need a prescription to get Kartal?

In all authorized markets, the medicine is only available with a prescription from a healthcare professional. It is not classified as an over-the-counter medication.

Q: Is Kartal similar to [Name of common alternative drug]?

Kartal's active ingredient, Nimesulide, is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Official information indicates it is a preferential inhibitor of the COX-2 enzyme, which is a feature that distinguishes its mechanism of action from some older NSAIDs.

Q: What common over-the-counter medicines should I check before taking Kartal?

Regulatory documents generally advise against taking Kartal with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This is done to reduce the overall risk of adverse effects. The regulatory concern requires an awareness of other NSAID ingredients to avoid accidental co-administration.

Q: Can people with high blood pressure take Kartal?

According to the official product information, the medicine is strictly contraindicated (must not be used) in patients with severe uncontrolled hypertension (very high blood pressure). For patients with pre-existing cardiovascular conditions, official guidance states that caution is required.

Q: Can I take Kartal with antacids?

While taking Kartal with antacids is not specifically listed as a contraindication, the active ingredient is often used alongside antiulcer agents to manage gastrointestinal effects. Studies suggest that the effectiveness of the medicine is not significantly altered by this type of co-administration.

Q: Can I take Kartal if I have kidney issues?

Official guidance on use conditions indicates that no dose adjustment is necessary for patients with mild to moderate kidney impairment. However, Kartal is strictly contraindicated (forbidden) for individuals with severe kidney impairment.

Q: What is the official safety classification of Kartal?

Kartal is officially classified as a prescription-only Non-Steroidal Anti-Inflammatory Drug (NSAID) in markets where it is authorized. Consistent with other NSAIDs, regulatory warnings advise against its use during the later stages of pregnancy due to documented risks to the developing fetal heart and kidneys.

Q: What is the legal status of Kartal in Europe (EMA)?

In European Member States where the medicine is authorized, Nimesulide-containing products are only available with a prescription. Following regulatory reviews, treatment is restricted to a maximum of 15 days for specific short-term uses.

Q: Is there a link between Kartal and sun sensitivity?

The regulatory information for the topical gel formulation includes a specific warning regarding sun exposure. The regulatory warning states that the treated area must be protected from direct and solarium sunlight to reduce the risk of photosensitivity (increased skin sensitivity to the sun).

Q: What happens if I take too much Kartal?

Official regulatory documents describe the potential symptoms of an overdose. These symptoms may include fatigue, drowsiness, nausea, vomiting, and stomach pain.

Q: Is it normal for Kartal to change the color of urine?

Regulatory safety information indicates that dark urine may be a potential sign of a serious, rare liver-related complication, which should be urgently reported as a serious event. This is a sign listed in official safety warnings.

Q: How do I know if I'm having a serious side effect?

Official regulatory warnings identify symptoms such as decreased hunger, vomiting, headache, stomach pain, tiredness, or dark urine as signs that should be urgently reported as a serious reaction. This information helps describe the specific warning signs listed in the official product information.

The official storage and disposal guidelines for Kartal are established by regulatory authorities to maintain product stability and ensure public safety.

Official Storage Requirements

Item	Requirement (Official Labeling)
Temperature	Store below 25 C (for oral forms) or Do not store above 30 C (for some topical forms).
Container & Protection	Keep the container tightly closed and store in the original package to protect the product from humidity and heat.
Child Safety	The medicine must be stored out of the sight and reach of children and secured by the instruction to Store locked up (P405 statement).

Official Disposal Rules

Unused or expired Kartal and its packaging must be disposed of according to official regulatory guidance.

• Mandatory Route: Disposal of contents and container must be through an approved waste disposal plant (P501 statement) or authorized collection method, adhering strictly to local laws.
• Environmental Restriction: To protect water systems, the product must not be discharged into drains, watercourses, or onto the ground (i.e., do not flush down the toilet or throw into household wastewater).